drugset
drugset / Trial / NCT01979484

Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations

NCT01979484 ↗

Phase 1 Completed 24 enrolled Presidio Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelBasic science

Summary

This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet.

Timeline

Start
2013-10
Primary completion
2013-11
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ravidasvir Small molecule 200 mg —

Indications

No indication recorded.